3
ESMO-MCBS v1.1
Scorecard version: 1
Indication details
- Tumour Type
- Gynaecological Malignancies
- Tumour Sub-type
- Ovarian Cancer
- Tumour stage
- Metastatic
- Combined Agent(s)
- Gemcitabine + carboplatin
- Control Arm
- Gemcitabine + carboplatin
- Treatment Setting
- Recurrent platinum-sensitive ovarian cancer
- Trial Name
- OCEANS
Primary Outcome(s)
- Primary Outcome(s)
- PFS (crossover allowed)
- Form(s)
- Form 2b
Outcome Data
- PFS Control
- 8.4 months
- PFS Gain
- 4 months
- PFS HR
- 0.48 (0.39-0.61)
- OS HR
- NS
Final Score (after adjustments)
- Preliminary non-curative score
- 3
- Final non-curative Score
- 3
DFS, disease-free survival; DoR, duration of response; EFS, event-free survival; HR, hazard ratio; ORR, overall response rate; OS, overall survival; pCR, pathologic complete response/remission; PFS, progression-free survival; QoL, quality of life; RFS, relapse-free survival; RR, response rate